It is very uncertain whether IV ferric carboxymaltose changes serious adverse events ‐ mild to moderate disease (16 weeks) compared with oral iron sulphate (very low certainty).
It is very uncertain whether IV iron sucrose changes serious adverse events ‐ mild to moderate disease (20 weeks) compared with oral iron sulphate (very low certainty).
It is very uncertain whether IV ferric carboxymaltose changes serious adverse events ‐ mild to moderate disease (12 weeks) compared with IV iron sucrose (very low certainty).
It is very uncertain whether summary of findings table ‐ Convalescent plasma changes serious adverse events compared with standard plasma (very low certainty).
Tacrolimus showed no clear difference in serious adverse events compared with beclometasone (low certainty).
It is very uncertain whether tacrolimus changes serious adverse events compared with placebo (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Oral 5‐ASA showed no clear difference in serious adverse events compared with SASP (low certainty).
Once daily dosing showed no clear difference in serious adverse events compared with conventional dosing (low certainty).
Oral 5‐ASA showed no clear difference in serious adverse events compared with comparator 5‐ASA (low certainty).
Oral 5‐ASA showed no clear difference in serious adverse events compared with placebo (low certainty).
Briakinumab showed no clear difference in serious adverse events compared with placebo (low certainty).
Ustekinumab showed no clear difference in serious adverse events compared with placebo (moderate certainty).
High‐dose corticosteroids probably leads to higher serious adverse events compared with moderate‐dose or no corticosteroids (moderate certainty).
Vedolizumab showed no clear difference in serious adverse events compared with placebo (moderate certainty).
Sarilumab showed no clear difference in serious adverse events ( compared with standard care/placebo (low certainty).
Clazakizumab showed no clear difference in serious adverse events ( compared with standard care/placebo (low certainty).
It is very uncertain whether olokizumab changes serious adverse events ( compared with standard care/placebo (very low certainty).
Siltuximab showed no clear difference in serious adverse events ( compared with standard care/placebo (low certainty).